Immuron Ltd
NASDAQ:IMRN

Watchlist Manager
Immuron Ltd Logo
Immuron Ltd
NASDAQ:IMRN
Watchlist
Price: 0.977 USD -7.83% Market Closed
Market Cap: 5.9m USD

Operating Margin

-73.5%
Current
Improving
by 66.4%
vs 3-y average of -139.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-73.5%
=
Operating Income
AU$-5.4m
/
Revenue
AU$7.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-73.5%
=
Operating Income
$-5.4m
/
Revenue
AU$7.3m

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Immuron Ltd
ASX:IMC
11.4m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
178.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.2B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.9B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in Australia
Percentile
44th
Based on 3 951 companies
44th percentile
-73.5%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Immuron Ltd
Glance View

Market Cap
5.9m USD
Industry
Biotechnology

Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The firm operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. The firm's flagship products include Travelan & Protectyn. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn is an anti-LPS antibodies, which target and remove harmful bacteria and LPS toxins in the gut. The firm focused on clinical development of three drug candidates and several in early-stage preclinical development.

IMRN Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-73.5%
=
Operating Income
AU$-5.4m
/
Revenue
AU$7.3m
What is Immuron Ltd's current Operating Margin?

The current Operating Margin for Immuron Ltd is -73.5%, which is above its 3-year median of -139.9%.

How has Operating Margin changed over time?

Over the last 3 years, Immuron Ltd’s Operating Margin has increased from -407.4% to -73.5%. During this period, it reached a low of -407.4% on May 30, 2022 and a high of -73.5% on Jul 30, 2025.

Back to Top